A Phase 3 Multicenter Open-label Study of Brigatinib(AP26113) versus Crizotinib in Patients with ALK-positiveAdvanced Lung Cancer

ARIAD Pharmaceuticals, Inc.0 个研究点目标入组 275 人开始时间: 2016年9月15日最近更新: 2022年4月19日

适应症

试验速览

阶段: 1 期
状态: 进行中（未招募）
发起方: ARIAD Pharmaceuticals, Inc.
入组人数: 275

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional clinical trial of medicinal product

入排标准

性别: All

入选标准

•1. Have histologically or cytologically confirmed stage IIIB (and not a candidate for definitive multimodality therapy) or stage IV NSCLC.
•2. Must have prior positive test results from an ALK test.
•3. Have sufficient tumor tissue available for central analysis.
•4. Have at least 1 measurable (i.e., target) lesion per RECIST v1.1.
•5. Recovered from toxicities related to prior anticancer therapy to NCI CTCAE v 4.0 grade =1.
•6. Are a male or female patient =18 years old.
•7. Have adequate organ function, as defined by the study protocol.
•8. Have Eastern Cooperative Oncology Group (ECOG) performance status <2.
•9. Have normal QT interval on screening ECG evaluation, defined as QT interval corrected (Fridericia) (QTcF) of =450 milliseconds (msec) in males or =470 msec in females.
•10. For female patients of childbearing potential, have a negative pregnancy test documented prior to randomization.
•11. For female and male patients who are fertile, agree to use a highly effective form of contraception, as defined by the study protocol.
•12. Provide signed and dated informed consent indicating that the patient has been informed of all pertinent aspects of the study, including the potential risks, and is willingly participating.
•13 Have the willingness and ability to comply with scheduled visit and study procedures.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 216
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 54

排除标准

•1. Previously received an investigational antineoplastic agent for NSCLC.
•2. Previously received any prior TKI, including ALK-targeted TKIs.
•3. Previously received more than 1 regimen of systemic anticancer therapy for locally advanced or metastatic disease.
•4. Received chemotherapy or radiation within 14 days of first dose of study drug, except stereotactic radiosurgery (SRS) or stereotactic body radiation therapy (SBRT).
•5. Received anti-neoplastic monoclonal antibodies within 30 days of the first dose of study drug.
•6. Had major surgery within 30 days of the first dose of study drug, minor surgical procedures such as catheter placement or minimally invasive biopsies are allowed.
•7. Have been diagnosed with another primary malignancy other than NSCLC, except for adequately treated non-melanoma skin cancer or cervical cancer in situ; definitively treated non-metastatic prostate cancer; or patients with another primary malignancy who are definitively relapse-free with at least 3 years elapsed since the diagnosis of the other primary malignancy.
•8. Have symptomatic CNS metastases (parenchymal or leptomeningeal) at screening or asymptomatic disease requiring an increasing dose of corticosteroids to control symptoms within 7 days prior to randomization.
•9. Have current spinal cord compression (symptomatic or asymptomatic and detected by radiographic imaging). Patients with leptomeningeal disease and without cord compression are allowed.
•10. Be pregnant, planning a pregnancy, or breastfeeding
•11. Have significant, uncontrolled, or active cardiovascular disease, as defined by the study protocol.
•12. Have uncontrolled hypertension.
•13. Have a history or the presence at baseline of pulmonary interstitial disease, drug-related pneumonitis, or radiation pneumonitis.
•14. Have an ongoing or active infection.
•15. Have a known history of human immunodeficiency virus (HIV) infection.
•16. Have a known or suspected hypersensitivity to brigatinib or its excipients and/or crizotinib or its excipients.
•17. Have malabsorption syndrome or other gastrointestinal (GI) illness or condition.
•18. Have any condition or illness that, in the opinion of the investigator, would compromise patient safety or interfere with the evaluation of the study drug.

研究者

发起方

ARIAD Pharmaceuticals, Inc.

相似试验

进行中（未招募）

1 期

A Phase 3 Multicenter Open-label Study of Brigatinib versus Crizotinib in ALK-positive Advanced Lung Cancer patientsALK positive Locally Advanced or Metastatic Non-small Cell Lung CancerMedDRA version: 21.1Level: PTClassification code 10059515Term: Non-small cell lung cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)

EUCTR2015-003447-19-NOARIAD Pharmaceuticals, Inc. (a wholly-owned subsidiary of Takeda Pharmaceutical Company Limited)270

进行中（未招募）

1 期

EUCTR2015-003447-19-ATARIAD Pharmaceuticals, Inc. (a wholly-owned subsidiary of Takeda Pharmaceutical Company Limited)270

进行中（未招募）

1 期

EUCTR2015-003447-19-NLARIAD Pharmaceuticals, Inc. (a wholly-owned subsidiary of Takeda Pharmaceuticals Company Limited)270

进行中（未招募）

1 期

EUCTR2015-003447-19-DKARIAD Pharmaceuticals, Inc. (a wholly-owned subsidary of Takeda Pharmaceutical Company Limited)270

进行中（未招募）

1 期

A Phase 3 Multicenter Open-label Study of Brigatinib versus Crizotinib in ALK-positive Advanced Lung Cancer patientsALK positive Locally Advanced or Metastatic Non-small Cell Lung CancerMedDRA version: 19.0Level: PTClassification code 10059515Term: Non-small cell lung cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)

EUCTR2015-003447-19-ESARIAD Pharmaceuticals, Inc.275